46 results about "Mouse Kidney" patented technology

The invention discloses a biological tissue mass spectrometry imaging method which comprises the following steps: (1) selecting in-vitro kidney tissues of a mouse, and slicing after freezing, thereby obtaining mouse kidney tissue slices; (2) selecting a corundum rod, attaching the mouse kidney tissue slices obtained in the step (1) onto the corundum rod, and naturally airing; (3) dripping an acriflavine solution onto the mouse kidney tissue slices, and standing, so that the solution uniformly diffuses; and (4) placing the corundum rod adhered with the mouse kidney tissue slices on which the acriflavine solution drips in a laser mass spectrometer for detecting, and processing mass spectrometric data ionized after laser analysis by virtue of software, thereby obtaining the imaging mass spectrum of the acriflavine-containing mouse kidney tissue slices. The method is rapid and direct, matrix interference and complicated sample pretreatment processes can be avoided, mass spectrometry signals can be regulated in time and space by the laser analysis post-ionization imaging technology, and thus optimization of the imaging mass spectrum is facilitated.

The invention provides a research method for applying TLR4 to curing acute kidney injury caused by sepsis, and relates to the technical field of medical treatment. The method comprises the steps of mouse septic AKI model building; animal modelling judgement; specimen collection; normal and septic AKI mouse kidney cell primary culture; TLR4 determination by means of immunohistochemistry (SP method)and semi-quantitation; Real-time PCR detection of expression change of VEGF, sFLT-1, TNF-alpha and TLR4mRNA of septic AKI mouse primary kidney cells; detection of protein level expression change of VEGF, sFLT-1, TNF-alpha and TLR4 of septic AKI mouse primary kidney cells through a Western-blot method; constructing VEGF gene eukaryotic expression plasmids and optimal silence mouse VEGF gene ShRNAexpression plasmids; experimental grouping; TLR4 cell treatment; index detection; verifying TLR4 target regulation on VEGR expression; searching for protein in interaction with the VEGF; discussing molecule mechanisms which is possibly involved in TLRs signal path adjustment of the VEGF. The method speculates that the VEGF and the TLR4 signal path are in interaction for regulating the acute kidneyinjury caused by sepsis and play a part in protection.

A polypeptide prepared from mouse ES cell strains by the SST method and a homologous polypeptide obtained from mouse kidney, human uterus, mouse fetus, human fetal liver and pancreas libraries; a cDNA encoding the polypeptide; a fragment selectively hybridizing with the sequence of the cDNA; a replication or expression plasmid containing the cDNA integrated thereinto; a host cell transformed with plasmid; an antibody against the polypeptide; and a pharmaceutical composition containing the polypeptide or the antibody.

The invention discloses use of NSC228155 in the preparation of a medicine for preventing and treating acute kidney injury, and particularly relates to application of NSC228155 for treating acute renalinjury by protecting renal tubular epithelial cells. NSC228155 can improve the renal function of a cis-platinum-induced acute kidney injury mouse model, improve the pathological changes of acute renal tubular injury, reduce the apoptosis of mouse kidney tissue, reduce the inflammatory response of kidney tissue, and improve the cis-platinum-induced mitochondrial function and oxidative stress status of the mouse renal cortex tissues and renal tubular epithelial cells and protect renal tubular epithelial cells.

The present invention relates to a small molecule polypeptide TP-7 having a function of inhibiting a renal fibrosis-promoting function of extracellular matrix tenascin C (TNC) and particularly to a use of the small molecule polypeptide TP-7 in preparation of medicines for treating chronic kidney diseases (CKD). An amino acid sequence of the polypeptide TP-7 is shown in SEQ ID NO.1. In multiple mouse kidney fibrosis models, the TP-7 has a significant effect, can obviously restore renal functions, inhibits progress of renal fibrosis, is also free of obvious toxic and side effects, and thus can be prepared into pharmaceutical preparations for treating the chronic kidney diseases.

The invention discloses application of NSC228155 in treating chronic renal interstitial fibrosis, and particularly relates to application of the NSC228155 in treating the chronic renal interstitial fibrosis by resisting inflammation and protecting renal tubular epithelial cells (RTECs). The NSC228155 can relieve pathological change of a chronic renal interstitial fibrosis mouse model, reduce the expression level of fibrosis factors of renal tissue of a mouse, reduce inflammatory reaction of renal tissue and fibroblasts, protect the RTECs in the fibrosis model and reverse the transdifferentiation effect of the RTECs.

The invention discloses an application of disulfiram to preparation of a drug for treating systemic lupus erythematosus. For the systemic lupus erythematosus, a lupus mouse model induced by pristane is taken as an experiment object. According to the application, the disulfiram can effectively improve the disease condition of a lupus mouse, and specific performances are as follows: (1) the urine protein level of the lupus mouse after being treated with the disulfiram is significantly reduced; (2) the disulfiram can reduce the level of a peripheral blood anti-dsDNA and the level of an inflammatory factor IL-1beta of the lupus mouse; and (3) after intervention is carried out by using the disulfiram, pathological damage to kidney of the lupus mouse is significantly reduced, and immune complexIgG and C3 deposits are also reduced.

The invention discloses a method for evaluating eye irritation by means of a mouse kidney cell system, and the method is applicable to evaluation of cosmetic raw material irritation, in particular to evaluation of eye irritation of surfactants. According to the method, when irritation of a test material to cells exists, the cells contract, fully-fused cells are damaged, and when fluorescein acts on damaged cell membranes, the damage degree of the cell membranes is indirectly reflected according to the amount of leaked fluorescein, so that irritation of the test material is represented. The test material used by the method is stable in population, reliable in source and high in fusing speed, a cell growth culturing membrane is easy to form, and a guarantee is provided for stability of a test; and when the mouse kidney cell system is used for evaluation of irritation damage of the surfactants, a result is in good correlation with a result of a rabbit eye animal test.

The invention discloses a mouse kidney in vivo microscopic imaging and tracing matching system. The mouse kidney in vivo microscopic imaging and tracing matching system includes a chassis, a column, asupport, a gripper and an observation ring which are arranged on the chassis, wherein one end of the support is arranged in a slide groove on the column and the other end of the support is provided with the gripper; the inner circle of the observation ring is ellipsoid, the mouse kidney is loaded on the inner circle of the observation ring, and the skin is fixedly fixed on the groove of the outerring of the observation ring; the gripper comprises a fixing claw and a movable jaw, a card plate is arranged on the gripper, and the card plate contacts with the groove of the ring outer of the observation ring. The technical scheme is reasonable in structure, convenient in fixing, capable of observing the inner ring close to the surface of the kidney, thereby increasing the reliability of the mouse kidney, and provides an ellipsoid observation ring to better mark the fixed site of the kidney surface, which is beneficial to the long-time tracing and observation of the migration and morphological changes of fluorescence-bearing cells in certain markers, and to advance the study of microscopic imaging and tracing in vivo in mice.

The invention provides a preparation method of metanephric mesenchyme cells. The method comprises the following steps: mating a Foxd1cre transgenic mouse with a DTRflox transgenic mouse, separating embryonic mouse kidneys, culturing embryonic kidney cells, and adding diphthera toxins to extract highly-pure Foxd1<+> metanephric mesenchyme cells. Compared with reported methods for separating specific cell phenotype metanephric mesenchyme cells, the method provided by the invention has the advantages of simplicity in operation, realization of simple components and high purity of the extracted Foxd1<+> metanephric mesenchyme cells, controllable extraction amount of the Foxd1<+> metanephric mesenchyme cells, and realization of large-scale production preparation of the Foxd1<+> metanephric mesenchyme cells.

The invention provides an application of tetrahydropalmatine in preparation of medicine for resisting cisplatin toxicity. The toxicity comprises kidney toxicity, ototoxicity and neurotoxicity. The research shows that tetrahydropalmatine has inhibition effect for OCT2 and MATE1, can antagonize the cytotoxicity caused by cisplatin, and obtains good verification for primary culture of a renal tubular epithelial cell model. By taking (-)-THP as a representative, the research finds that tetrahydropalmatine has good protection effect for mice kidney damage caused by cisplatin, so that tetrahydropalmatine and cisplatin are combined, accumulation of cisplatin at kidney, cochlear cells and dorsal root ganglion is reduced, so that the expection result for preventing or reducing cisplatin toxicity can be achieved. The application develops the novel purpose of the tetrahydropalmatine, because that OCT2 is highly expressed by kidney, cochlear cells and dorsal root ganglion, expression of OCT2 is lacked on tumor cells, cisplatin has certain passive permeability, so that tetrahydropalmatine and cisplatin are combined, toxicity due to cisplatin is decreased, and cisplatin antineoplastic effect is not reduced.

The invention discloses a separation and culture method of a mouse kidney clear cell carcinoma circulating tumor cell line and kidney clear cell carcinoma circulating tumor cells, and relates to the technical field of separation and culture of tumor cells. The mouse kidney clear cell carcinoma circulating tumor cell line is circulating tumor cells of an in-situ kidney cancer NOD/SCID mouse. The separation and culture method of the circulating tumor cells mainly comprises the following steps of: firstly, infecting a human kidney clear cell carcinoma cell line 786-O with viruses, so that the human kidney clear cell carcinoma cell line is stably converted into green fluorescent protein and has Puromycin resistance, and culturing the cell line; and then establishing a mouse model, collecting peripheral blood of the mouse, and culturing and separating the peripheral blood to obtain the kidney cancer circulating tumor cells. The separation and culture method disclosed by the invention is simple and easy to operate, and the circulating tumor cells obtained by separation can be subjected to normal leaflet culture and can be widely applied to clinical research.

The invention discloses a mimic epitope peptide and application thereof. The amino acid sequence of the mimic epitope peptide is as shown in SEQ No.1. The mimic epitope peptide can be used as the antigen to immunize animals to prepare a polyclonal antibodies and can be used for preparing drugs for preventing and/or treating chronic organ fibrotic diseases. After a mouse kidney fibrosis model builtby a unilateral ureteral obstruction method is processed by the mimic epitope peptide, MASSON shows that mouse kidney fibrosis degree is evidently relieved, immunohistochemistry shows that the expression of protein related to fibrosis in kidney tissue is lowered evidently, macrophage number in the kidney tissue and the spleen is lowered evidently, and mechanism researches show that the mouse signal channel is inhibited.

The invention discloses an application of Balanophora extract in preparation of an anti-renal fibrosis drug. The Balanophora extract is water extract or water extraction and alcohol precipitation extract. The Balanophora water extraction and alcohol precipitation extract (BPP) can inhibit UUO-induced mouse renal interstitial injury and fibrosis, and has a certain protection effect on the UUO-induced mouse renal function. Further researches show that the BPP inhibits the expression of Collagen I, Collagen III and Collagen IV to inhibit the renal fibrosis; By adopting the BPP, in an animal experiment process, death of a mouse is not found, and obvious abnormal liver and kidney functions of the mouse are not observed, which indicates that the extract has better safety. The Balanophora water extraction and alcohol precipitation extract can be applied to preparation of anti-renal fibrosis drugs and pharmaceutical compositions.

The invention relates to the use of tubatoxin in preparation of drugs treating acute kidney injury. After treatment with a small dose (250ppm) of tubatoxin, the mouse kidney injury situation can be obviously improved, and the levels of blood urea nitrogen (BUN) enzyme and creatinine (Cr) are obviously lowered.

The invention relates to the technical field of immunofluorescent staining of kidneys, and discloses a perfusion fixation method for effectively improving and observing immunofluorescence of primary cilia in the kidney of a mouse. The method comprises the following steps: after the abdominal cavity of the mouse is anesthetized, quickly opening the chest to expose the heart of the mouse, opening the left heart tip, inserting a perfusion needle connected with a peristaltic pump into the left ventricle from the opening, perfusing a certain amount of PBS for cleaning and a certain amount of 10% neutral formalin for fixing on the whole body at a constant speed at a flow speed of 40-60 [mu]l/s, taking out the kidney of the mouse when the whole body of the mouse is stiff, and fixing the kidney in a 10% neutral formalin solution for a certain time. It is found that the quantity distribution of the primary cilia of the kidney of the mouse after constant-speed perfusing is greatly improved; and compared with traditional simple whole-body tissue perfusion fixation, the cell proportion of the primary cilia is improved from 55% to 90-98%, and the correctness of a test for researching the pathogenesis of ciliary lesion diseases is greatly improved. Meanwhile, according to the above technical scheme, experimental operation repeatability is good, and a good foundation is laid for follow-up study on pathogenesis of ciliary lesion diseases.

The invention discloses a nano-enzyme as well as a preparation method and application thereof, and the nano-enzyme comprises rhodium nano-particles and serine combined on the surfaces of the rhodium nano-particles. The nano-enzyme (Rh-Ser) provided by the invention has an ultra-small size which is lower than a renal tubule filtration threshold value; meanwhile, due to the fact that serine has the capacity of targeting renal injury molecularly 1 (KIM-1) expressed by damaged renal tubules, modification of serine can enable the rhodium nano-particles to have certain renal targeting capacity, and the rhodium nano-particles can be effectively enriched in the kidneys of damaged mice; a large amount of active oxygen or active nitrogen in the renal canaliculus is removed to relieve and treat glycerol-induced acute kidney injury, and the compound has excellent anti-inflammatory ability. In addition, the Rh-Ser has a good treatment effect, and meanwhile, the Rh-Ser has excellent biocompatibility and biological safety.

The invention relates to application of an anaphalis virgata n-butyl alcohol extract. The anaphalis virgata n-butyl alcohol extract is obtained from anaphalis virgata through 70% ethanol thermal extraction, and in-vitro cell experiments show that the anaphalis virgata n-butyl alcohol extract has the effects of reducing blood sugar and relieving kidney lesions caused by high glucose injury. According to the extract, the glucose consumption of rat myoblasts (L6) and the Na <+> - K <+> - ATP enzymatic activity of a high-glucose induced high-glucose injured mouse kidney cell (MPC-5) model can be remarkably increased, and the effects of reducing blood sugar and regulating a polyol pathway to relieve kidney lesions caused by high-glucose injury are shown.

The invention relates to application of ouabain in preparation of an anti-kidney stone kidney tubule injury drug. The experiment shows that the plant-derived ouabain compound adopted can effectively improve the decline in vitality of human proximal kidney tubule epithelial cells caused by calcium oxalate monohydrate, release of lactate dehydrogenase in cells and apoptosis caused thereby. At the same time, the ouabain also can alleviate the mouse weight loss and kidney function decrease caused by glyoxylic acid, reduce the accumulation of calcium oxalate crystals in the kidney caused by glyoxylic acid, and the resulting mouse kidney tubule injury and kidney apoptosis. At present, the drug which effectively resists the kidney tubule injury caused by kidney stone is deficient, especially in the case of small molecule drugs, the ouabain has good development value and application prospects.

The invention belongs to the field of traditional Chinese medicines, and particularly relates to a poria cocos and semen cuscutae renal diabetes formula and application thereof, and the poria cocos and semen cuscutae renal diabetes formula comprises the following main active ingredients in parts by weight: 10-60 parts of semen cuscutae, 10-60 parts of poria cocos, 5-30 parts of schisandra chinensis, 5-60 parts of lotus seeds, 10-60 parts of Chinese yam and 10-60 parts of radix trichosanthis. The invention further provides a preparation method and application of the poria cocos and semen cuscutae renal diabetes formula. Animal experiments show that the poria cocos and semen cuscutae renal diabetes formula can effectively improve obesity symptoms of mice with db/db2 type diabetic nephropathy, effectively reduce the blood fat level of the mice, especially effectively reduce the urine protein excretion rate of the mice, and has no damage to liver and renal functions of the mice. Under an electron microscope, it can be observed that foot process fusion in kidney podocytes of mice in a traditional Chinese medicine group is obviously improved, and it is indicated that the poria cocos and semen cuscutae renal diabetes formula has the kidney protection effect. Therefore, the poria cocos and semen cuscutae renal diabetes formula disclosed by the invention can be used for reducing proteinuria of diabetic nephropathy and playing a role in protecting kidneys by improving podocyte injury.

A transgenic mouse has a genome that includes the entire gene region of human transforming growth factor beta-1 (human TGFβ1) located downstream of a mouse Podocin promoter such that expression of the human TGFβ1 is controlled by the mouse Podocin promoter. The human TGFβ1 contains 7 exons and 6 introns, the human TGFβ1 is expressed in a kidney of the mouse as non-active TGFβ1 and becomes active TGFβ1 extracellularly, and the transgenic mouse spontaneously develops renal fibrosis.